Anglo-Swedish drugmaker AstraZeneca on Thursday upped its earnings forecasts for the year as surging sales of cancer medicines offset plummeting sales of COVID vaccines.
The uptick in AstraZeneca’s revenues was largely driven by a 17% increase in sales of cancer drugs at constant exchange rates, to $4.66 billion, on the back of 53% higher sales of its cancer immunotherapy drug Imfinzi. Excluding lower sales of COVID vaccines across the globe, AstraZeneca’s sales increased in all regions worldwide, apart from China, as the firm showed particularly strong growth in emerging markets.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »
출처: MarketWatch - 🏆 3. / 97 더 많은 것을 읽으십시오 »